David Fiorentino

Long-term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase 2 Results from Double-blind and Open-Label Extension Studies

Objective To evaluate long-term safety and efficacy of dazukibart, a novel anti-interferon beta monoclonal antibody, in adults with moderate-to-severe dermatomyositis (DM). Methods Participants from two cohorts of DM (skin-predominant, SP and muscle-predominant, MP), completing a...